These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8981334)

  • 1. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
    Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
    Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OESCLIM: an advanced delivery system for HRT.
    Munoz A
    Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OESCLIM: summary of tolerability and safety.
    Brackman F
    Maturitas; 1999 Nov; 33 Suppl 1():S83-8. PubMed ID: 10661619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
    Erianne JA; Winter L
    Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
    Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
    Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OESCLIM: pre-clinical and clinical profile.
    Guy M
    Maturitas; 1999 Nov; 33 Suppl 1():S49-55. PubMed ID: 10661615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
    Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
    Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
    Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
    Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
    Leodolter S; Sainz H; Moll-Schüler I; Mach R
    Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
    al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
    Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes].
    Rotta L; Matĕchová E
    Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms.
    Gadomska H; Barcz E; Cyganek A; Leocmach Y; Chadha-Boreham H; Marianowski L
    Curr Med Res Opin; 2002; 18(2):97-102. PubMed ID: 12017217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
    Rachev E
    Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.
    Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW
    Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
    Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
    Gordon SF
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
    Guichard JP; Sauron R; Jones AB
    J Clin Pharmacol; 1999 Aug; 39(8):811-6. PubMed ID: 10434233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
    Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.